You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated Rodent Research Home Cage Monitoring System for Animal Welfare

    SBC: TRICORDER ARRAY TECHNOLOGIES LLC            Topic: 100

    PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries

    SBC: VenoStent, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Peripheral artery disease (PAD) affects nearly 12 million people in the United States. One of the most common surgical therapies is peripheral artery bypass grafting (PABG). Some patients are eligible for less invasive treatment options like angioplasty, but patients with calcified lesions are not. In patients that do receive PABG, approximately 20% fail within the first y ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. BIONIC BAROREFLEX SYSTEM FOR BLOOD PRESSURE CONTROL

    SBC: TK TX COMPANY            Topic: N/A

    Patients with multiple system atrophy (MSA), a sporadic and progressive neurodegenerative disorder, suffer from orthostatic hypotension, postprandial hypotension and supine hypertension. Hypotension causes presyncopal symptoms usually within seconds of standing and requires the patient to sit or lie down to prevent syncope. Supine hypertension reduces leep quality through excessive nocturnal diur ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDCD

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Broad Spectrum Bitter Taste Antagonists Discovery

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDCD

    Principal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) and Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challenges: food insecurity, poor nutritional health, and poor compliance with medication use, particularly among children and the elderly. Sugar and salt, the mainstays to addres ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Cancer dual-targeting of an infectivity-enchanced CRAd

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A number of characteristics of the Adenovirus type 5 (Ad5) make it an optimal gene therapy/virotherapy vector suitable for a wide array of cancer therapeutic approaches. Despite these advantages, overall ifficacy remains limited by sub-optimal adenovirus delivery to cancer tissues. One conceptual approach to overcome this limitation is to achieve an amplificati ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Cancer dual-targeting of an infectivity-enhance CRAd

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Studies of the molecular mechanisms underlying neoplastic transformation and progression have resulted in the understanding that cancer is a genetic disease, deriving from the accumulation of a series of acquired genet ic lesions. Despite advances in chemotherapy, radiation delivery, and surgical treatment regimens, survival from many advanced cancers remains ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Cardiac Interactions of New Adriamycin Analogs and Taxol

    SBC: GEM Pharmaceuticals            Topic: N/A

    DESCRIPTION (provided by applicant): Paclitaxel (Taxol) and doxorubicin (DOX, Adriamycin) are chemotherapeutic drugs used in treatment of metastatic breast cancer. When used individually, they produce a 30-40 percent response rate. When combined, using high doses of DOX (450-550 mg/m2), the response rate is increased to 85-95 percent. This represents a significant improvement in tumor responsivene ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage

    SBC: VasaMetrix            Topic: 107

    PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: Technology Commercialization Partners LLC            Topic: NHLBI

    ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government